Larry Clark, MD
Gastroenterology · Lynchburg, VANPI 1780659508
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $982,803 of the $1,246,851 with a category attached, or 78.8%. 35 manufacturers reported payments, led by AbbVie at 24.4% of the total. Among gastroenterology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,951 payments — averaging $639.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$304K
- Pfizer$238K
- Johnson & Johnson$213K
- E.r. Squibb & Sons, L.L.C.$179K
- Lilly USA, LLC$158K
- Phathom Pharmaceuticals, Inc.$115K
- plus $39K from 29 others
Across 575 payments — averaging $12,651 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$4.2M
- Bristol Myers Squibb$962K
- Takeda Pharmaceuticals U.S.A., Inc.$808K
- Pfizer$639K
- E.r. Squibb & Sons, L.L.C.$163K
- Ironwood Pharmaceuticals, Inc$145K
- plus $333K from 8 others
What the payments were for
- Consulting fees$47,0984%
- Speaking & faculty fees$982,80379%
- Travel & lodging$178,92514%
- Food & beverage$37,9903%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 599 | $304,039 |
| Pfizer(2 entities) | 373 | $238,185 |
| Johnson & Johnson | 196 | $213,295 |
| E.r. Squibb & Sons, L.L.C. | 155 | $179,071 |
| Lilly USA, LLC | 192 | $158,301 |
| Phathom Pharmaceuticals, Inc. | 134 | $114,904 |
| Janssen Scientific Affairs, LLC | 27 | $24,498 |
| Bristol Myers Squibb | 70 | $9,151 |
| Exact Sciences | 2 | $1,800 |
| Ironwood Pharmaceuticals, Inc | 40 | $853 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $529 |
| Regeneron Healthcare Solutions, Inc. | 11 | $270 |
| QOL Medical, LLC | 14 | $242 |
| Aimmune Therapeutics, Inc. | 11 | $209 |
| Covidien LP | 3 | $171 |
| Sanofi | 8 | $169 |
| Nestle Healthcare Nutrition Inc. | 15 | $161 |
| Ardelyx, Inc. | 8 | $142 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $118 |
| Ipsen Biopharmaceuticals, Inc | 6 | $118 |
| Merck | 6 | $94 |
| UCB, Inc. | 6 | $90 |
| Ferring Pharmaceuticals Inc. | 5 | $68 |
| Daiichi Sankyo Inc. | 3 | $59 |
| Intercept Pharmaceuticals, Inc. | 4 | $57 |
| Blueprint Medicines Corporation | 2 | $40 |
| Medtronic | 2 | $40 |
| Amgen | 2 | $37 |
| Olympus America Inc. | 2 | $33 |
| Braintree Laboratories, Inc. | 2 | $28 |
| Gilead | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Shionogi Inc | 1 | $12 |
| Mallinckrodt Hospital Products Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,246,851 in reported general payments places this provider in the 95th percentile of 473 gastroenterology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $416,969 |
| LinzessLinaclotide | 12 | $9,635 |
| Mesalamine | 19 | $3,786 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 23 | $1,565 |
| Omeprazole | 75 | $1,051 |
| Sucralfate | 16 | $891 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 30 | $504 |
| Dicyclomine Hcl | 15 | $256 |
| Pantoprazole Sodium | 15 | $179 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $213,295 | $416,96916 claims |
| AbbVieLinzess | $304,039 | $9,63512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 473 gastroenterology providers in Virginia.
Other gastroenterology in Lynchburg
- Arun SanyalRichmond$855K
- Mitchell ShiffmanNewport News$635K
- Bryan SauerCharlottesville$540K
- Michael RyanNorfolk$335K
- Brian WentworthCharlottesville$276K
- Vanessa ShamiCharlottesville$210K
- Ali SiddiquiFairfax$167K
- Michael FuchsRichmond$126K
- Michael ManetasRichmond$125K
- Kenneth JosovitzWoodbridge$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.